Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Revolution Medicines Inc
42ZCurrent price
49 EUR
+2.79 EUR (+6.06%)
Last closed
53.5 USD
Company
www.revmed.com
ISIN
US76155X1000
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
8 103 074 816 USD
Yield for 12 month
+155.76 %
1Y
3Y
5Y
10Y
15Y
42Z
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. Address: 700 Saginaw Drive, Redwood City, CA, United States, 94063
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
60.08 USDP/E ratio
–Dividend Yield
–Current Year
+11 580 000 USD
Last Year
+35 380 000 USD
Current Quarter
–
Last Quarter
–
Current Year
+2 271 000 USD
Last Year
+25 724 000 USD
Current Quarter
-2 797 000 USD
Last Quarter
-2 763 000 USD
Key Figures 42Z
1 year
3 years
5 years
10 years
EBITDA
-569 468 992 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-24.95 %
PEG Ratio
–
Return On Equity TTM
-40.73 %
Wall Street Target Price
60.08 USD
Revenue TTM
742 000 USD
Book Value
9.77 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-95.2 %
Dividend Yield
–
Gross Profit TTM
-217 693 000 USD
Earnings per share
-3.72 USD
Diluted Eps TTM
-3.72 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics 42Z
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 42Z
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation 42Z
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
8424.0482
Price Sales TTM
10920.586
Enterprise Value EBITDA
-9.7077
Price Book MRQ
4.7898
Financials 42Z
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 42Z
For 52 weeks
18 USD
51 USD
50 Day MA
45.27 USD
Shares Short Prior Month
16 342 734
200 Day MA
38.34 USD
Short Ratio
14.51
Shares Short
16 662 899
Short Percent
10.63 %
BeatStart